文献速递免疫规划传染病防控与疫情报告

基于外膜囊泡的脑膜炎球菌疫苗MenBvac的免疫原性持久性与菌株覆盖:诺曼底战役的经验

Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: Lessons of the Normandy campaign.
PubMed 文献 · Vaccine · 2017-06-16

MenBvac®是基于外膜囊泡(OMV)的脑膜炎球菌疫苗,2006至2012年用于控制法国诺曼底暴发的克隆性B群疫情。研究对1-5岁接种首剂并完成2+1+1程序的儿童队列检测血清杀菌活性(SBA),发现末次加强后1年和4年分别仅47.9%和31.3%受试者SBA滴度达到保护水平;对完全匹配P1.7,16的菌株均具保护滴度,对部分匹配VR1或VR2的菌株覆盖率较高(75-100%)。作者结论认为OMV疫苗诱导的SBA滴度持续时间短,可能需要重复加强接种,但菌株覆盖率可能高于预期。

要点

  • 末次加强后1年仅47.9%、4年仅31.3%受试者SBA滴度达到保护水平。
  • 对完全匹配P1.7,16的B或C群菌株,所有血清均显示保护性SBA滴度。
  • 作者认为OMV疫苗诱导的SBA滴度持续时间短,可能需要重复加强注射。

核心结论

  • OMV疫苗诱导的SBA滴度持续时间短,可能需要重复加强注射,但菌株覆盖率可能高于预期。

研究设计与样本

  • 研究纳入两个儿童队列,均在1-5岁接种首剂MenBvac®并完成2+1+1程序,分别于末次加强后1年或4年提供血样检测SBA。

主要发现

  • 末次加强后1年,47.9%受试者SBA滴度达到保护水平;末次加强后4年,31.3%受试者SBA滴度达到保护水平。
  • 所有血清对完全匹配P1.7,16的B或C群菌株均显示保护性SBA滴度。
  • 对部分匹配VR1或VR2的菌株,除一个菌株外,其余菌株的血清保护率均高(75-100%)。
  • 将数据外推至4CMenB/Bexsero®的OMV组分,基于PorA匹配,当前B群菌株中14.5%可被覆盖(不考虑其他三种疫苗组分的覆盖)。

临床怎么用

  • 作者认为OMV疫苗可能需要重复加强注射以维持保护性SBA滴度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: MenBvac® is an outer membrane vesicle (OMV)-based meningococcal vaccine. From 2006 to 2012, it was used to control a clonal B outbreak in Normandy (France). We aimed to analyse the durability of the response against the epidemic strain and coverage beyond the vaccine strain. These data should help to optimize the use of OMV-containing vaccines, such as the new 4CMenB/Bexsero® recombinant vaccine. METHODS: Serum bactericidal activity (SBA) was measured in two cohorts of children who received their first dose of MenBvac® at 1-5years of age and accepted to provide a blood sample either one or four years after a 2+1+1 schedule. All sera were tested against the outbreak strain. Sera from responder subjects were also tested against 12 additional B or C strains which were chosen to entirely, partially, or not at all match the two variable regions (VR1 and VR2) of the PorA vaccine strain. RESULTS: Only 47.9% and 31.3% of subjects showed an SBA titre consistent with protection one and four years, respectively, after the last boost. Protective SBA titres were observed in all sera against B or C strains that entirely matched P1.7,16, and was high (75-100%) for all but one strain that partially matched VR1 or VR2. Extrapolating our data to the OMV component of 4CMenB/Bexsero® suggests that 14.5% of the current B strains would be covered based on PorA matching to the OMV component of 4CMenB/Bexsero® (regardless of the coverage of the three other vaccine components). CONCLUSIONS: Our data confirm that OMV-based vaccines elicit short-lasting SBA titres and may require repeated booster injections. However, strain coverage may be greater than expected.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sevestre J, Hong E, Delbos V, et al. Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: Lessons of the Normandy campaign. Vaccine. 2017. PMID: 28624305. doi:10.1016/j.vaccine.2017.05.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。